GH vs PSNL

Key Takeaways

• Guardant Health (GH) generated full-year 2025 revenue of approximately $982 million, reflecting 33% year-over-year growth, driven by accelerating oncology test volumes and the rapid commercial launch of its Shield blood-based colorectal cancer screening test.
• Personalis (PSNL) posted 2025 revenue of roughly $69.6 million, a decline of nearly 18% from the prior year, though clinical test volumes surged nearly 400% as its NeXT Personal minimal residual disease (MRD) platform gained physician adoption.
• Both companies operate in the precision oncology diagnostics space, yet GH benefits from a diversified, multi-product revenue base approaching $1 billion annually, while PSNL is earlier in its commercial evolution with a concentrated MRD (minimal residual disease) strategy.
• Guardant Health ended 2025 with approximately $1.3 billion in cash and marketable securities; Personalis held roughly $240 million — a meaningful disparity in financial firepower for commercial expansion and R&D (research and development).
• GH carries a beta of 1.59 versus PSNL's 2.24, indicating Personalis exhibits substantially higher volatility relative to the broader market.
• Analyst consensus rates GH a "Strong Buy" with a price target implying double-digit upside, while PSNL holds a "Buy" consensus with a more modest implied return.

Introduction

The precision oncology sector has drawn intense investor attention as liquid biopsy and genomic testing technologies reshape how cancer is detected, monitored, and treated. GH (Guardant Health) and PSNL (Personalis) represent two distinct profiles within this rapidly evolving industry. Guardant Health has matured into a commercial powerhouse with a broad portfolio spanning therapy selection, recurrence monitoring, and early cancer screening. Personalis, by contrast, is a smaller, more focused player betting heavily on ultrasensitive MRD testing. This stock comparison examines how these two companies differ in scale, growth trajectory, risk profile, and market positioning — offering traders and long-term investors a clear, data-driven view of their relative performance and prospects.

GH Overview and Recent Performance

Guardant Health is a leading precision oncology company headquartered in Palo Alto, California, offering blood- and tissue-based cancer tests across the full continuum of care. Its flagship products include the Guardant360 liquid biopsy platform for therapy selection, Guardant Reveal for MRD detection and monitoring, and Shield — an FDA (U.S. Food and Drug Administration)-approved blood test for colorectal cancer screening. The company also maintains a robust biopharma and data services segment, partnering with major pharmaceutical firms for companion diagnostic development and real-world data analytics.

In recent quarters, GH has delivered accelerating financial momentum. Full-year 2025 revenue reached approximately $982 million, a 33% increase over 2024, with fourth-quarter revenue alone climbing 39% year-over-year to roughly $281 million. Oncology test volumes grew 34% for the full year, while Shield screening volumes expanded dramatically from a near-zero base in early 2024 to approximately 87,000 tests in 2025. Non-GAAP (non-Generally Accepted Accounting Principles) gross margins held strong at around 66%, and the company has guided for 2026 revenue between $1.25 billion and $1.28 billion, implying continued 27–30% growth. Recent strategic developments include a collaboration with Merck for companion diagnostics, Shield's inclusion in National Comprehensive Cancer Network guidelines, partnerships with Quest Diagnostics and PathGroup to broaden screening access, and the acquisition of MetaSight Diagnostics. With a market capitalization near $19.5 billion and approximately $1.3 billion in cash reserves, GH has considerable resources to fund its expanding commercial footprint.

PSNL Overview and Recent Performance

Personalis, based in Fremont, California, specializes in advanced genomics for precision oncology, with a primary focus on its NeXT Personal platform — an ultrasensitive, tumor-informed liquid biopsy test for detecting MRD, monitoring therapy response, and surveilling for cancer recurrence. The company also offers ImmunoID NeXT, a tissue-based tumor profiling service used by biopharma partners for drug development and clinical trials. Personalis operates under a concentrated "Win-in-MRD" strategy, directing most of its resources toward establishing NeXT Personal as a standard of care in solid tumor monitoring.

PSNL's recent financial picture reflects a company in transition. Full-year 2025 revenue declined roughly 18% to $69.6 million, pressured by the wind-down of legacy customer relationships — notably with Natera — and lower pharma testing volumes. However, clinical test adoption has been a bright spot: the company delivered approximately 16,233 clinical tests in 2025, representing nearly 400% growth over the prior year, with sequential quarter-over-quarter volume acceleration. A pivotal milestone arrived in late 2025 when Personalis secured Medicare coverage for breast cancer surveillance using NeXT Personal, followed by lung cancer coverage in early 2026. The company ended 2025 with around $240 million in cash after raising approximately $109 million through an ATM (At-The-Market) equity offering. For 2026, management has guided for total revenue of $78–$80 million and clinical revenue of $10–$11 million — a projected fivefold increase — while acknowledging that gross margins will remain compressed (15–20%) as the company invests heavily ahead of full reimbursement. With a market capitalization near $1.26 billion and a beta of 2.24, PSNL exhibits significantly more price volatility than its larger peer.

Trending AI Robots

In a market environment where speed, pattern recognition, and data-driven discipline increasingly separate successful traders from the rest, Tickeron's Trending AI Robots page offers a curated window into the platform's most capable AI-powered trading agents. Tickeron hosts hundreds of AI Trading Bots covering thousands of tickers, yet only those demonstrating the strongest alignment with current market conditions earn placement in this featured section. These bots employ distinct trading styles — including swing trading, trend following, and intraday price-action strategies — across timeframes ranging from 5 minutes to several days. Performance metrics such as annualized returns, win rates, and profit factors vary widely by strategy, with top-performing bots historically delivering annualized returns exceeding 70% and win rates above 65%. Each AI robot is powered by Tickeron's proprietary Financial Learning Models (FLMs), which continuously retrain on real-time market data. For traders seeking an analytical edge in comparing stocks like GH and PSNL, exploring the Trending AI Robots section can reveal which bots are currently trading these or related tickers with statistically backed conviction.

Head-to-Head Comparison

The contrast between GH and PSNL is defined primarily by scale, maturity, and diversification. Guardant Health operates a multi-pronged revenue engine: oncology testing (therapy selection and MRD monitoring), screening (Shield), and biopharma data services. This breadth partially insulates the company from weakness in any single segment and creates multiple avenues for growth. Personalis, on the other hand, is almost entirely dependent on the success of NeXT Personal in the MRD market — a high-upside but concentrated bet.

From a growth driver perspective, GH is capitalizing on the rapid adoption of Shield, which has been described as one of the most successful diagnostic launches in recent history, alongside steady volume increases in its core oncology business. PSNL's growth narrative hinges on converting clinical test volume acceleration into reimbursed revenue now that Medicare coverage for breast and lung cancer surveillance has been secured.

Risk profiles diverge meaningfully. GH, while still unprofitable on a GAAP basis, has a clear path toward narrowing losses, with free cash flow burn improving year-over-year and the core oncology business expected to reach free cash flow breakeven. PSNL carries higher execution risk: gross margins are under pressure, cash usage is projected at approximately $100 million in 2026, and the company must demonstrate it can translate clinical adoption into sustainable reimbursement revenue before its capital runway narrows. PSNL's beta of 2.24 versus GH's 1.59 further underscores the higher volatility and sharper price swings investors have experienced in Personalis shares.

Sector exposure is similar — both are precision oncology diagnostics companies — but market sentiment differs. GH benefits from broad institutional coverage (25 analysts, "Strong Buy" consensus) and a demonstrated capacity to raise capital on favorable terms, including a $350 million convertible note offering and a $300 million equity raise in late 2025. PSNL has 6 analysts covering it with a "Buy" consensus, and notable institutional backing from Merck (which holds roughly 15.8% of shares) and ARK Invest, though the company relied on ATM equity sales at a weighted-average price of $8.43 per share to bolster its balance sheet.

Tickeron AI Verdict

Based on observable market data, trend consistency, and relative positioning, Tickeron's AI-driven analytical framework would likely favor GH in the current environment. Guardant Health exhibits stronger and more predictable revenue growth, a diversified product portfolio that reduces single-indication risk, higher gross margins, a substantially larger cash reserve, and a lower beta — all factors that algorithmic models typically associate with greater trend stability and lower downside volatility. Personalis, while demonstrating impressive clinical volume momentum and securing pivotal Medicare coverage wins, remains in an earlier and more uncertain phase of its commercial journey, with compressed margins and higher cash-burn intensity relative to its revenue base. That said, probabilistic models would not dismiss PSNL outright; rather, they would likely assign it a higher risk-reward profile suited to strategies with greater volatility tolerance. For traders seeking exposure to precision oncology with comparatively lower beta and stronger revenue visibility, GH appears better positioned within the current market regime.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations